BONE TARGETED DRUG DELIVERY

MUSCULOSKELETAL NANOMEDICINE

 

Meet The Team

Seth Harlem

 

cofounder & CEO

  • Grey LinkedIn Icon

Mo Chen, PhD, MBA

cofounder & Chief Science Officer

  • Grey LinkedIn Icon

Edward Puzas, PhD

 

Wakenda Tyler, MD

Service Chief, Orthopaedic Oncology 

Columbia University Medical Center

MuSCULOSKELETAL

Conditions

Taithera is a revolutionary nanomedicine targeted drug delivery platform for bone. 

ONcology

Targeting primary and metastatic bone cancers.

OSTEOPOROSIS

Taithera can improve low bone density associated with aging.

FRACTURE HEALING

We aim to reduce nonunions, and significantly increase speed of healing for all fractures.

 
 

Meet The Team

Seth Harlem

 

cofounder & CEO

  • Grey LinkedIn Icon

Mo Chen, PhD, MBA

cofounder & Chief Science Officer

  • Grey LinkedIn Icon

Edward Puzas, PhD

 

Wakenda Tyler, MD

Service Chief, Orthopaedic Oncology 

Columbia University Medical Center

Meet The Team

Seth Harlem, MBA

 

cofounder & CEO

  • Grey LinkedIn Icon

Mo Chen, PhD, MBA

cofounder & Chief Science Officer

  • Grey LinkedIn Icon

Scientific Advisory Board

Monica Fornier, MD

Breast Cancer Oncologist

 

Memorial Sloan Kettering Cancer Center

Edward Puzas, PhD

Donald and Mary Clark Professor of Orthopaedics

University of Rochester School of Medicine & Dentistry 

Edward Puzas, PhD

Donald and Mary Clark Professor of Orthopaedics

University of Rochester School of Medicine & Dentistry 

Wakenda Tyler, MD

Chief of Service, Orthopaedic Oncology  

Columbia University Medical Center

NEWS & AWARDS

March 2019

Brooklyn, NY

Taithera is pleased to announce the opening of its new laboratory at the Downstate Biotechnology Incubator in Brooklyn, NY.  

October 20, 2017

Boston, MA 

Taithera Presents at the Pfizer sponsored DDS Technology Soapbox at the Partnership Opportunities in Drug Delivery (PODD) Conference alongside Sonoran Biosciences, Subcuject, BioHealthways, Vesselon, Pendant Biosciences, and Lindy Biosciences.    

September 8, 2017

Rochester, NY 

 

 

 

Taithera's Technology Featured in ACS Nano

 

Inventors Dr. Danielle Benoit, Dr. Edward Puzas, et al from the University of Rochester recently had the paper, Fracture-Targeted Delivery of β‐Catenin Agonists via Peptide - Functionalized Nanoparticles Augments Fracture Healing  accepted by ACS Nano.  It is a great honor to be recognized by such a prestigious journal, and Taithera is proud to be a part of the team.      

July 26, 2017

New York, NY

 

 

 

 

Dr. Mo Chen, Taithera's cofounder and Chief Science Officer published in ACS Nano, a leading nanotechnology journal.  Dr. Chen is a corresponding author on the groundbreaking paper, Exosomes Mediate Epithelium-Mesenchyme Crosstalk in Organ Development.  ACS Nano is published by the American Chemical Society.

June 23, 2017

Rochester, NY

 

Taithera, Inc. invited to present at JazzTech 2017 on June 23rd at the University of Rochester.  JazzTech 2017 was presented by URVentures and Cranberry Capital, in partnership with Rochester Institute of Technology & New York Medical Angels.

June 20, 2017

San Diego, CA

 

Taithera, Inc. Wins First Place at the RESI SAN DIEGO 2017 INNOVATION CHALLENGE

Taithera CEO, Seth Harlem (right) and Chief Science Officer, Mo Chen (center) receive First Place at the 2017 RESI Innovation Challenge on June 19th.  

June 1, 2017

 

Taithera, Inc. Selected to Present at The RESI SAN DIEGO 2017 INNOVATION CHALLENGE

April 7, 2017

Taithera CEO, Seth Harlem presented at the 2017 New York City Economic Development Corporation's Entrepreneurship Lab Bio & Health Tech Pitch Day on April 6, 2017.  

April 3, 2017

May 16, 2016

PARTNERS

 
 

GET IN TOUCH

We're scientists & entrepreneurs. We love discussing our research & ways we may be able to work together.

347-404-4408